Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection by Sukupolvi-Petty, Soila et al.




Functional analysis of antibodies against dengue
virus type 4 reveals strain-dependent epitope
exposure that impacts neutralization and protection
Soila Sukupolvi-Petty
Washington University School of Medicine in St. Louis
James D. Brien
Washington University School of Medicine in St. Louis
S. Kyle Austin
Washington University School of Medicine in St. Louis
Bimmi Shrestha
Washington University School of Medicine in St. Louis
Sherri Swayne
Integral Molecular
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Sukupolvi-Petty, Soila; Brien, James D.; Austin, S. Kyle; Shrestha, Bimmi; Swayne, Sherri; Kahle, Kristen; Doranz, Benjamin J.;
Johnson, Syd; Pierson, Theodore C.; Fremont, Daved H.; and Diamond, Michael S., ,"Functional analysis of antibodies against dengue




Soila Sukupolvi-Petty, James D. Brien, S. Kyle Austin, Bimmi Shrestha, Sherri Swayne, Kristen Kahle,
Benjamin J. Doranz, Syd Johnson, Theodore C. Pierson, Daved H. Fremont, and Michael S. Diamond
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/3437
  Published Ahead of Print 19 June 2013. 
2013, 87(16):8826. DOI: 10.1128/JVI.01314-13. J. Virol. 
Fremont and Michael S. Diamond
Doranz, Syd Johnson, Theodore C. Pierson, Daved H.
Bimmi Shrestha, Sherri Swayne, Kristen Kahle, Benjamin J. 
Soila Sukupolvi-Petty, James D. Brien, S. Kyle Austin,
 
Impacts Neutralization and Protection
Strain-Dependent Epitope Exposure That
Dengue Virus Type 4 Reveals 
Functional Analysis of Antibodies against
http://jvi.asm.org/content/87/16/8826






This article cites 88 articles, 38 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 





ber 1, 2014 by W










ber 1, 2014 by W






Functional Analysis of Antibodies against Dengue Virus Type 4
Reveals Strain-Dependent Epitope Exposure That Impacts
Neutralization and Protection
Soila Sukupolvi-Petty,a James D. Brien,a S. Kyle Austin,a Bimmi Shrestha,a Sherri Swayne,e Kristen Kahle,e Benjamin J. Doranz,e
Syd Johnson,f Theodore C. Pierson,g Daved H. Fremont,b,d Michael S. Diamonda,b,c
Departments of Medicine,a Pathology & Immunology,b Molecular Microbiology,c and Biochemistry and Molecular Biophysics,d Washington University School of Medicine,
St. Louis, Missouri, USA; Integral Molecular, Inc., Philadelphia, Pennsylvania, USAe; MacroGenics, Inc., Rockville, Maryland, USAf; Laboratory of Viral Diseases, NIAID, National
Institutes of Health, Bethesda, Maryland, USAg
Although prior studies have characterized the neutralizing activities of monoclonal antibodies (MAbs) against dengue virus
(DENV) serotypes 1, 2, and 3 (DENV-1, DENV-2, and DENV-3), few reports have assessed the activity of MAbs against DENV-4.
Here, we evaluated the inhibitory activity of 81 newmouse anti-DENV-4MAbs. We observed strain- and genotype-dependent
differences in neutralization of DENV-4 byMAbsmapping to epitopes on domain II (DII) and DIII of the envelope (E) protein.
Several anti-DENV-4MAbs inefficiently inhibited at least one strain and/or genotype, suggesting that the exposure or sequence
of neutralizing epitopes varies within isolates of this serotype. Remarkably, flavivirus cross-reactive MAbs, which bound to the
highly conserved fusion loop in DII and inhibited infection of DENV-1, DENV-2, and DENV-3, more weakly neutralized five
different DENV-4 strains encompassing the genetic diversity of the serotype after preincubation at 37°C. However, increasing
the time of preincubation at 37°C or raising the temperature to 40°C enhanced the potency of DII fusion loop-specific MAbs and
some DIII-specific MAbs against DENV-4 strains. Prophylaxis studies in two newDENV-4mouse models showed that neutral-
ization titers of MAbs after preincubation at 37°C correlated with activity in vivo. Our studies establish the complexity of MAb
recognition against DENV-4 and suggest that differences in epitope exposure relative to other DENV serotypes affect antibody
neutralization and protective activity.
Dengue virus (DENV) is amember of the Flaviviridae family ofRNA viruses and is genetically related to other human patho-
gens of global concern, including yellow fever, West Nile (WNV),
and Japanese encephalitis viruses. In nature, DENVdisease occurs
exclusively in humans afterAedes aegypti orAedes albopictusmos-
quito inoculation, with clinical disease ranging from a debilitating
febrile illness (dengue fever [DF]) to a life-threatening hemor-
rhagic and capillary leak syndrome (dengue hemorrhagic fever
[DHF]/dengue shock syndrome [DSS]). No approved antiviral
treatment is currently available, although candidate tetravalent
vaccines are in advanced clinical trials (reviewed in references 1
and 2). Because of the increased geographic range of its mosquito
vectors, urbanization, and international travel, DENV continues
to spread worldwide and now causes an estimated 390 million
infections and 500,000 cases of DHF/DSS per year, with 3.6 billion
people at risk (3, 4). Given that themost advanced live-attenuated
DENV vaccine candidate showed a poor 30% overall efficacy rate
in a recently published phase 2b clinical trial (5), there is an urgent
need for understanding the correlates of protection, especially
those of neutralizing antibodies.
DENV is an enveloped virus with a single-stranded, positive-
polarity RNA genome. Based on experiments with DENV-1 and
DENV-2 isolates, the mature DENV virion is500 Å in diameter
with a highly organized outer protein shell, a 50-Å lipid mem-
brane bilayer, and a nucleocapsid core (6–8). At 28°C, mature
DENV virions are covered by 90 antiparallel envelope (E) protein
homodimers, arranged flat along the surface with quasi-icosahe-
dral symmetry. At higher temperatures (e.g., greater than 35°C),
structural changes occur and DENV virions acquire a bumpy ap-
pearancewith a diameter of550Å and some exposedmembrane
(9, 10). The immature virion,which lacks cleavage of the premem-
brane (prM) protein, has a rough surface with 60 spikes, each
composed of three prM-E heterodimers (11, 12). Exposure to
mildly acidic conditions in the trans-Golgi network promotes vi-
rus maturation through a structural rearrangement of the flavivi-
rus E proteins and cleavage of prM tomembrane (M) protein by a
furin-like protease (13–16). The ectodomain ofDENVEprotein is
comprised of three discrete domains (17–20). Domain I (DI) is a
central, eight-stranded-barrel. Domain II (DII) is a long, finger-
like protrusion from DI with the highly conserved fusion peptide
at its distal end and an N-linked glycan that recognizes DC-SIGN
(21–24). Domain III (DIII), which adopts an immunoglobulin-
like fold, has been suggested to contain cell surface receptor rec-
ognition sites (25–27).
Significant diversity exists among DENV strains, including
four unique serotypes (DENV-1, -2, -3, and -4) that differ at the
amino acid level by 25 to 40%. Additional complexity occurs
within each serotype, as genotypes vary by up to 3% at the amino
acid level (28, 29). DENV-4 has been suggested to have four dis-
tinct genotypes (I, II, III, and sylvatic), whose circulation patterns
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differ in time and space: genotype I includes strains from the Phil-
ippines, Thailand, Vietnam,Malaysia, Sri Lanka, and India; geno-
type II is composed of two lineages with strains from Thailand,
Malaysia, Taiwan, and the Americas; genotype III includes Thai
strains from1997 to 2001; sylvatic strainswere isolated frommon-
keys or mosquitoes in the 1970s in Malaysia (30). Although syl-
vatic DENV strains show the greatest sequence differences among
the genotypes within a serotype, these viruses still can replicate
and cause disease in humans (30–32).
Infection with one DENV serotype is believed to confer long-
term durable immunity against strains of the homologous but not
heterologous DENV serotypes due to the specificity of neutraliz-
ing antibodies and protective CD8 T cells (33). Recently, in the
context of DENV-1, DENV-2, and DENV-3, the question of how
intergenotypic or even strain variation within a serotype affects
the protective efficacy of neutralizing antibodies has begun to be
addressed. Neutralizing antibodies or polyclonal serum with in-
hibitory activity against one genotype within a serotypemay show
significant loss of potency against heterologous genotypes (34–
38). This concept may be important, because the development of
tetravalent DENV vaccines with prototype strains assumes that
neutralizing antibody responses, which are lower during vaccina-
tion than natural infection, will protect completely against all ge-
notypes within a given serotype (5, 39).
While our laboratory and others have generated panels of in-
hibitory monoclonal antibodies (MAbs) that react specifically
with DENV-1, DENV-2, or DENV-3, to date, remarkably few
strongly neutralizing type-specific anti-DENV-4MAbs have been
reported: these include three unmapped mouse MAbs (UH-6C3,
D4-II-12B2, and D4-I-11D11) (40, 41), two chimpanzee MAbs
(5D9 and 5H2), one of which is localized to an epitope in domain
I of the E protein (42, 43), and one human MAb DV22.3, which
recognizes an epitope in DI-DII (44). In the current study, we
developed a panel of 81 newDENV-4mouseMAbs and examined
their neutralization potentials initially against a genotype II strain
(DENV-4 1036; Indonesia 1976) that was used for immunization.
Somewhat surprisingly, in our initial functional screens, we iden-
tified only six type-specificDENV-4MAbs that efficiently blocked
infection of DENV-4 1036, with the majority of these mapping to
distinct epitopes on DIII of the E protein. Because so few of our
type-specific MAbs inhibited DENV-4 efficiently, we tested the
inhibitory activities of four previously generated cross-reactive
fusion loop-specific MAbs (E60, E86, E106, and E119); although
these MAbs were originally generated against WNV (45), they
have strongly neutralizing activities against other DENV sero-
types, with some demonstrating therapeutic activity against
DENV-2-induced vascular leakage syndrome in mice (46). These
fusion loop MAbs also exhibited weakly neutralizing activity
against DENV-4 1036 and several additional strains, including
those belonging to the other DENV-4 genotypes. However, when
we increased the time and/or temperature of preincubation, all
fusion loop-specific cross-reactiveMAbs showed enhanced inhib-
itory activity against the DENV-4 strains. These time and temper-
ature of incubation experimental results suggest that at steady
state, DENV-4 strains may exist as a unique ensemble of confor-
mations compared to other DENV serotypes, which would ob-
scure epitope exposure and limit neutralizing activities of fusion
loop MAbs.
To begin to assess the significance of these findings, we devel-
oped two new lethal peripheral infection models in AG129 IFN-
R/  IFN-R/ mice with DENV-4 strains (H-241 and
TVP-376) corresponding to distinct genotypes and used them to
assessMAb protection by passive transfer. Remarkably, the highly
cross-reactive fusion loop MAbs, which potently inhibited infec-
tion of DENV-1, DENV-2, and DENV-3, showed marginal pro-
tection against genotype I DENV-4 H-241 and enhanced protec-
tion against genotype II DENV-4 TVP-376. These in vivo results
correlatedwith focus reduction neutralization titers ofMAbs after
preincubation at 37°C. Our studies establish the complexity of
MAb recognition against the strains and genotypes of theDENV-4
serotype and suggest that differences inDENV-4 epitope exposure
relative to otherDENV serotypesmodulate the protective capacity
of antibodies.
MATERIALS AND METHODS
Cells and viruses. BHK21-15 and Vero cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS; Omega Scientific) and antibiotics (penicillin G and strepto-
mycin). Raji-DC-SIGN cells were cultured in RPMI 1640 medium sup-
plemented with 10% FBS and antibiotics. DENV-4 strains used in this
study included 1036 (genotype II; Indonesia, 1976), H-241 (genotype I;
Philippines, 1956), TVP-376 (genotype II; Puerto Rico, 1982), TVP-986
(genotype I; Brazil, 1982) (47, 48), and P75-514 (sylvatic; Malaysia, 1975)
(30). DENV strains from other serotypes (DENV-1, 16007; DENV-2,
16681; DENV-3, 16652) were obtained from colleagues (A. de Silva, Uni-
versity of North Carolina, and R. Tesh, University of Texas Medical
Branch). All stock viruses were propagated in C6/36 Aedes albopictus cells
according to established protocols (49).
DENV-4 MAbs. To generate anti-DENV-4 MAbs, C57BL/6 mice de-
ficient in IFN- receptors (Ifnar/) were infected with 105 PFU of a
mixture (1:1) of DENV-4 strains 1036 and H-241 via the intraperitoneal
route and rechallenged 3weeks later with the same strains. Subsets ofmice
with serum showing the highest binding titer to permeabilized Raji-DC-
SIGN cells infected with DENV-4 strain 1036 (assayed at a dilution of
1:10,000) were immunized with purified DENV-4 DIII (50 g; strain
1036) in phosphate-buffered saline (PBS) as a final intravenous boost.
Three days later, splenocytes were fused to P3X63Ag8.6.5.3myeloma cells
by using polyethylene glycol 1500 (50). Hybridoma cells producing anti-
DENV-4 MAbs (see Table S1 in the supplemental material) were sub-
cloned by limiting dilution and isotyped using an enzyme-linked immu-
nosorbent assay (ELISA) kit (Southern Biotech). The fusion loop-specific
MAbs (E60, E86, E106, and E119) cross-react with all DENV serotypes
and have been described previously (45). Unless otherwise indicated, all
MAbs were purified from hybridoma supernatants by protein A or pro-
tein G immunoaffinity chromatography.
In vitro neutralization assays. Focus reduction neutralization titer
(FRNT) assays were performed with the different DENV-4 strains and
MAbs on Vero cells in a manner analogous to that described previously
for WNV (51). Serial dilutions of purified MAbs or hybridoma superna-
tants were mixed with 102 focus-forming units (FFU) of different
DENV-1, DENV-2, DENV-3, or DENV-4 viruses for specified times (1 or
3 h) and temperatures (37 or 40°C). Subsequently, virus-MAb mixtures
were added to Vero cell monolayers for 1 h, and then a 1% carboxymeth-
ylcellulose overlay was added. Two days later, the overlays were removed
and monolayers were fixed with 1% paraformaldehyde (1 hour at room
temperature), permeabilized with 0.1% saponin in PBS, and incubated
with human-mouse chimeric WNV E18 MAb (200 ng/ml) (45), which
recognizes the conserved fusion loop epitope. Following several washes,
wells were incubated with horseradish peroxidase-conjugated anti-hu-
man IgG antibody (Sigma; 250 ng/ml in saponin buffer) for 1 h at room
temperature. Wells were washed, and infectious foci were visualized with
TrueBlue substrate (KPL) after a 10-minute incubation at room temper-
ature. Wells were rinsed with water and analyzed with a Biospot counter
(Cellular Technology) and Immunocapture software. Neutralization
MAb Neutralization of DENV-4
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curves (the percent reduction in spot numbers in virus samples preincu-
bated with MAbs compared to medium alone) were graphed using Prism
software, and the 50% and 90% effective concentration (EC50 and EC90)
values were calculated by nonlinear regression using a variable slope.
E gene sequencing. DENV-4 E genes were amplified by reverse tran-
scription-PCR (RT-PCR) using primers (see Table S2 in the supplemental
material), a high-fidelity Taq polymerase, and RNA extracted directly
from infected C6/36 cells. Each amplicon was sequenced on both strands
by conventional capillary sequencing on an Applied Biosystems 3730 ge-
netic analyzer using previously reported primers (30, 34). The resulting
sequence reads were assembled, and the E gene sequences were aligned
using the Lasergene suite (DNAStar).
Domain mapping by yeast surface display. The DNA fragments en-
coding amino acid residues 1 to 292 (DI-DII) and 293 to 409 (DIII) of the
DENV-4 E protein were amplified from DENV-4 strain 1036 by RT-PCR
with KpnI and XhoI or BamHI and XhoI sites added at the 5= and 3= ends,
respectively. The PCRproductwas cloned as a downstream fusion toAga2
and Xpress epitope tag genes in the yeast surface display vector pYD1
(Invitrogen) and transformed into Saccharomyces cerevisiae strain
EBY100 (Invitrogen) to generate yeast that expressed DENV-4 DI-DII or
DIII or the E ectodomain, as described previously (49, 52).
Amino acid mapping of epitopes by shotgun mutagenesis and ex-
pression inmammalian cells.ADENV-4 prM-E protein expression con-
struct (strain TVP-376) was subjected to high-throughput alanine-scan-
ning mutagenesis to generate a comprehensive mutation library. Primers
were designed to mutate each residue within prM-E to alanine, with ala-
nine codons mutated to serine. In total, 660 DENV-4 mutant proteins
with sequence confirmation (	97% coverage) were generated and ar-
rayed into 384-well plates (one clone per well). Anti-DENV-4MAbs were
tested for reactivity against either the entire library of mutations or a
selected subset of the library containing the most relevant clones. Each
prM-E mutant was transfected into HEK-293T cells and allowed to ex-
press for 22 h. Cells then were fixed in 4% (vol/vol) paraformaldehyde
(Electron Microscopy Sciences) and permeabilized with 0.1% (wt/vol)
saponin (Sigma) in PBS plus calcium and magnesium (PBS). Cells
were stained with purified MAb DV4-E75 (0.2 g/ml) or DV4-E88 (0.2
g/ml) or hybridoma supernatant DV4-E4 (1:30), DV4-E29 (1:90), DV4-
E33 (1:180), DV4-E40 (1:270), DV4-E76 (1:60), DV4-E78 (1:30), DV4-
E87 (1:60), or DV4-E121 (1:60) diluted in 10% normal goat serum (NGS;
Sigma) and 0.1% saponin, pH 9.0. Primary antibody concentrations were
determined using an independent immunofluorescence titration curve
against wild-type DENV-4 prM-E to ensure that signals were within the
linear range of detection. Antibodies were detected using 3.75 g/ml of
AlexaFluor 488-conjugated secondary antibody (Jackson ImmunoRe-
search Laboratories) in 10% NGS (Sigma) and 0.1% saponin. Cells were
washed three times with PBS supplemented with 0.1% saponin, 1 mM
MgCl2, and CaCl2 followed by two washes in PBS. The mean cellular
fluorescence was detected using the a high-throughput flow cytometer
(HTFC; Intellicyt). Antibody reactivity against each mutant E protein
clone was calculated relative to wild-type E protein reactivity by subtract-
ing the signal from mock-transfected controls and normalizing to the
signal from wild-type prM-E-transfected controls. Mutations were iden-
tified as critical to theMAb epitope if they did not support reactivity of the
test MAb but did support reactivity of other DENV-4 MAbs. This coun-
terscreen strategy facilitates the exclusion of E mutants that are locally
misfolded or have expression defects (53).
Immunostaining of DENV-infected cells. To assess binding of
DENV-4MAbs to differentDENV strains, Raji DC-SIGN-RorC6/36 cells
were infected at a multiplicity of infection (MOI) of 0.5 or 1. Depending
on the strain, cells were harvested 48, 72, or 96 h after infection. Cells were
washed, fixed in PBS with 1% paraformaldehyde, permeabilized, incu-
bated with MAbs, and processed by flow cytometry as described previ-
ously (35).
Generation of MAb-resistant virus escape mutants. DENV-4 (1036
or TVP-376; 5 105 PFU) was incubated with 25g/ml of MAb DV4-75
or DV4-E88 for 1 h at 37°C in DMEM. The mixture was added to 5 105
Vero cells in a 6-well plate. After infection for 2 h at 37°C, wells were
washed thrice with DMEM, and fresh medium containing 5 g/ml of
MAb was added. Virus growth under antibody selection proceeded for 72
h at 37°C. At each passage, half of the supernatant was mixed 1:1 with 10
g/ml of MAb for 1 h. The remaining half was stored at 80°C. After
three to six passages under MAb selection, virus-containing supernatants
were tested by plaque reduction assay for escape from neutralization of
DV4-75 or DV4-88. After confirming the escape phenotype, an aliquot of
the supernatant was used for a Vero cell plaque assay under MAb selec-
tion. Plaque-purified viruswas amplified further underMAb selection (25
g/ml) overnight at 37°C. Vero cells were scraped from wells, and total
cellular RNA was isolated using an RNeasy kit (Qiagen). cDNA was am-
plified with random hexamers as well as a DENV-4 primer by using a
SuperScript III first-strand synthesis system for RT-PCR (Invitrogen) and
served as a template for PCR amplification using forward and reverse
primers (see Table S2 in the supplemental material). Amplicons were
sequenced, and the neutralization escapemutant sequence was compared
to the parent virus stock that was passaged in parallel in the absence of
MAb selection.
Mouse experiments.Allmouse studies were approved and performed
according to the guidelines of theWashington University School of Med-
icine Animal Safety Committee. Ifnar/ mice on the C57BL/6 back-
ground were a gift of Jonathan Sprent (The Scripps Research Institute).
The IFN-R/  IFN-R/ mice on a 129 Sv background (AG129)
have been described previously (54). All mice were housed in pathogen-
free barrier facilities. In prophylaxis experiments, mice were administered
a single dose of individualMAbs via the intraperitoneal route 1 day before
infection. AG129mice were challenged with DENV-4H-241 (genotype I)
or DENV-4 TVP-376 (genotype II) intravenously, and mortality was
monitored.
Generation of mouse-adapted DENV-4 strains. To develop a mouse
model of DENV-4 infection with the H-241 genotype I strain, virus was
passaged once in AG129 newborn pups after intraperitoneal infection;
moribund mice were sacrificed and brains were harvested, homogenized,
and virus was clarified by centrifugation (1,600  g for 5 min). The su-
pernatant was used to infect 6-week-old AG129 mice via an intravenous
route. Brains from mice that succumbed to infection were harvested and
serially passaged in 6-week-old AG129 for two additional rounds using
the same protocol. Virus isolated from the brains of AG129 mice infected
at passage five was used to infect C6/36 cells and generate a virus stock
used for experiments.
The TVP-376 genotype II mouse model was developed using a differ-
ent approach. TVP-376 was amplified in C6/36 cells, and virus was con-
centrated from supernatant by ultracentrifugation (67,000  g for 3 h
over a 25% glycerol cushion in 10 mM Tris, 150 mM NaCl, and 1 mM
EDTA in an SW32 rotor). Six-week-old AG129 mice were infected with
1 104 PFU of TVP-376 virus via the intravenous route. Four days later,
mice were bled and serum was added to C6/36 cells to generate a seed
stock that was purified by ultracentrifugation and used for infection of
AG129 mice.
Statistical analysis. All data were analyzed using Prism software
(GraphPad, San Diego, CA). Kaplan-Meier survival curves were analyzed
by the log rank test. Log EC50 values were compared using Student’s t test
when comparing two samples or a one-way analysis of variance when
comparing more than two samples.
Nucleotide sequence accession numbers.TwonewE gene sequences,
TVP-376 and TVP-986, were deposited in GenBank with accession num-
bers of KC963424 and KC963425, respectively.
RESULTS
Functional properties of newly generated MAbs against
DENV-4. In prior studies, we generated type-specific and cross-
reactive neutralizing MAbs against DENV-1, DENV-2, and
DENV-3 after immunization of Ifnar/ C57BL/6 mice with live
Sukupolvi-Petty et al.
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DENV and recombinant E proteins (35, 37, 38). As a first step
toward creating an analogous panel of MAbs that neutralized
DENV-4 infection, we infected Ifnar/ C57BL/6 mice with a
mixture of the DENV-4 strains 1036 (genotype II) and H-241
(genotype I) (Table 1) and boostedmice with homologous viruses
and recombinant DIII. Although DENV-4 failed to cause a lethal
infection in Ifnar/ mice, it replicated to higher titers than in
wild-type (WT) mice, which resulted in the induction of a stron-
ger neutralizing antibody response (data not shown). After
screening more than 6,000 hybridoma clones as part of 10 inde-
pendent fusions, we isolated 81 new MAbs that recognized per-
meabilized cells infected with DENV-4 (see Table S1 in the sup-
plemental material). Somewhat surprisingly (compared to studies
with newly generated MAbs against other DENV serotypes [35,
37, 38]), after a 1-h preincubation at 37°C, only six (DV4-E3,
DV4-E33, DV4-E75, DV4-E76, DV4-E88, and DV4-E121) MAbs
inhibited infection of DENV-4 1036 as neat hybridoma superna-
tant by greater than 90% in focus reduction assays, with only a
subset showing an ability to completely neutralize DENV-4 infec-
tion (Table 2, Fig. 1, and data not shown). The remainder of the
panel had less inhibitory activity against DENV-4 1036 when used
under similar conditions (Table 2 and data not shown).
Because these results were unexpected, we questioned whether
it was intrinsically more difficult for MAbs to inhibit DENV-4
than other serotypes. We reasoned this was possible, as we previ-
ously had difficulty isolating potently neutralizing antibodies
against hepatitis C virus (HCV), a distantly relatedmember of the
Flaviviridae family (55). To begin to assess this, we tested whether
MAbs recognizing the highly conserved fusion loop on domain II
neutralized infection of DENV-4. We utilized a panel of cross-
reactive fusion loop-specific MAbs that we had generated previ-
ously after sequential infection of C57BL/6 mice with WNV and
DENV-2 (45). Four of these MAbs (E60, E86, E106, and E119)
were selected for testing with DENV-4, because these efficiently
neutralized (EC50 values from 17 to 612 ng/ml) infection of
DENV-1, DENV-2, and DENV-3 (Fig. 2A and Table 3), with one
MAb (E60) having postexposure therapeutic activity against
DENV-2 in a mouse model of DSS (46, 56). Remarkably, despite
binding efficiently to DENV-4-infected cells (Fig. 2B), these four
MAbs showed relatively weak inhibitory activities (EC50 of 822 to
2,786 ng/ml and EC90 of 	5,000 ng/ml) against DENV-4 1036
after a 1-h preincubation at 37°C (Fig. 2C and Table 4).
Neutralization of DENV-4 by fusion loopMAbs is enhanced
by increasing the time and temperature of preincubation. One
possible explanation as to why the fusion loop MAbs neutralized
DENV-1, DENV-2, and DENV-3 but not DENV-4, despite bind-
ing to infected cells, was that the fusion loop epitope was not
equivalently accessible on the surface of the DENV-4 virion as on
the other DENV serotypes. Recent studies with WNV, DENV-1,
DENV-2, andHCVhave suggested that increasing the time and/or
TABLE 1 Characteristics of DENV-4 strains used in the studya
Virus Origin, yr Genotype Reference(s)
GenBank accession
no(s).
1036 Indonesia, 1976 II 34 U18429
H-241 Philippines, 1956 I 30, 34 AY947539, U18433
TVP-376 Colombia, 1982 II Unpublished KC963424
TVP-986 Brazil, 1982 II 47 KC963425
P75-514 Malaysia, 1975 Sylvatic 30 JF262780
a The genotypes were assigned based on alignment of E gene nucleotide sequences and
creation of a dendrogram. The results were confirmed using the Genotype
Determination and Recombination Detection online software from the Virus Pathogen
Resource (http://www.viprbrc.org/). The TVP-376 sequence has not been published
and was obtained from the World Arbovirus Collection.








DV4-E3 94 IgM DI-II DENV-1, -2, and -3
DV4-E4 84 IgG1 DI-II DENV-1, -2, and -3
DV4-E27 68 IgG2a DI-II DENV-1, -2, and -3
DV4-E29 69 IgG1 DIII None
DV4-E33 90 IgG2a DIII None
DV4-E40 79 IgG2a DIII None
DV4-E68 63 IgG2a DIII None
DV4-E75 100 IgG3 DIII None
DV4-E76 91 IgG2c DIII DENV-2
DV4-E78 79 IgG2c DIII DENV-2
DV4-E87 68 IgG2c DIII None
DV4-E88 100 IgG2c DIII None
DV4-E121 100 IgG2c DIII None
a Undiluted hybridoma supernatant (1 to 10 g/ml) was incubated with 102 FFU of
DENV-4 (strain 1036) for 1 h at 37°C. Virus-MAb mixtures were added to Vero cell
monolayers for 1 h at 37°C prior to addition of a methylcellulose overlay (described in
Materials and Methods). DENV-infected foci were stained with a human-mouse
chimeric E18 MAb. The percent neutralization was determined compared to medium
alone. Results are representative of three independent experiments.
b The MAb isotype was determined using a commercial ELISA kit.
c Domain localization was determined by yeast surface display or mapping with mutant
structural proteins (see Fig. 4). DV4-E75 and DV4-E88 did not bind to DIII when
expressed on the surface of yeast.
d Cross-reactivity to other DENV serotypes was established after intracellular staining of
C6/36 cells infected with DENV-1 (strain 16007), DENV-2 (strain 16681), or DENV-3
(strain 16652).
FIG 1 Neutralization of DENV-4 by type-specific MAbs. Increasing concen-
trations of purified MAbs (DV4-E75, DV4-E76, and DV4-E88) were mixed
with 102 PFU of DENV-4 strain 1036 for 1 h at 37°C, and inhibition was
assessed in a FRNT assay in Vero cells and compared to virus that was incu-
bated with no antibody. The graph was generated after regression analysis
using Prism statistical software. The data are representative of at least three
independent experiments performed in duplicate.
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ber 1, 2014 by W












ber 1, 2014 by W






temperature of preincubation facilitates exposure of buried
epitopes on different virion conformational ensembles, which re-
sults in enhanced neutralizing activity of someMAbs (57–60). To
test this hypothesis, we repeated the experiments with DENV-4
1036 and E60, E86, E106, or E119 for a longer time (37°C, 3 h) or
at a higher temperature (40°C, 1 h) for preincubation. Notably,
preincubation of the fusion loop MAbs for 3 h at 37°C slightly
improved neutralization of DENV-4 1036 (EC50 values 3- to
4-fold lower than with the 1-h incubation), although three (E60,
E86, and E119) of the four MAbs still failed to achieve a measur-
able EC90 value (Table 4). Preincubation ofDENV-4 1036with the
fusion loop MAbs at 40°C for 1 h more strongly enhanced their
inhibitory activities (Fig. 2C, EC50 values 24- to 82-fold lower than
at 37°C incubation; P 
 0.05). Remarkably, the 40°C incubation
improved the capacity to neutralize most of the DENV-4 virus
within the population, as the EC90 values now ranged from 125 to
442 ng/ml (Table 4). In comparison, changing the time or tem-
perature of incubation had small effects on the activities of se-
lected type-specific neutralizing MAbs DV4-E75 (2- to 2.5-fold
decrease in EC50 and EC90 values; P	 0.05) and DV4-E88 (2- to
1.5-fold change in EC50 and EC90 values; P	 0.05).
Effects of time and temperature of preincubation on MAb
neutralization of other DENV-4 strains. Neutralization of
DENV-1, DENV-2, and DENV-3 infection byMAbs can vary in a
genotype-dependent manner (35–38, 60). Given this observation,
we assessed whether the preincubation conditions differentially
affected neutralization by cross-reactive fusion loopMAbs of sev-
eral genetically distinct DENV-4 strains (Tables 4 and 5). We
tested four additional strains (H-241, TVP-376, TVP-986, and
P75-514 [Table 1]), corresponding to threeDENV-4 genotypes (I,
II, and sylvatic), which varied from strain 1036 by 0.4% (TVP-376
and TVP-396), 3% (H-241), and 4% (P75-514) at the amino acid
level for the E protein.When these DENV-4 strains were preincu-
bated with fusion loopMAbs (E60, E86, E106, and E119) for 1 h at
37°C, we observed weak neutralizing activity for H-241 (EC50 of
4,500 ng/ml; EC90 of 	5,000 ng/ml), TVP-376 (EC50 of 509 to
1,165 ng/ml; EC90 of	5,000 ng/ml), and TVP-986 (EC50 of 458 to
900 ng/ml; EC90 of	5,000 ng/ml). Under the same preincubation
conditions, higher levels of neutralization were observed against
the sylvatic strain P75-514 (EC50 of 98 to 267 ng/ml; EC90 of 1,312
to 2,317 ng/ml).
When experiments were repeated with longer preincubation
times, analogous to the findings with DENV-4 strain 1036, we
observed modestly improved inhibitory activity by fusion loop
MAbs against TVP-376, TVP-986, H-241, and P75-514. Preincu-
bation for 3 h at 37°C improved neutralization of DENV-4 TVP-
376 (EC50 values 4- to 7-fold lower than with the 1-h incubation),
and three of the four (E60, E86, and E106) achieved measurable
EC90 values (2,103 to 3,523 ng/ml) (Table 5). Similar results were
observed with DENV-4 P75-514 (EC50 values 4- to 6-fold lower
and EC90 values 4- to 8-fold lower than with the 1-h incubation at
37°C; P 
 0.05), although smaller effects were observed with
H-241, which still remained relatively resistant to neutralization.
In comparison, a longer incubation at 37°C improved the inhibi-
tory activity of the fusion loopMAbs against DENV-4 TVP-986 to
an even greater level (EC50 values 9- to 35-fold lower thanwith the
1-h incubation; P
 0.05).
Enhanced neutralization with fusion loop-specific MAbs also
was observed after preincubation of different DENV-4 strains at
40°C. Preincubation for 1 h at 40°C improved neutralization of
TVP-376 (EC50 values 57- to 105-fold lower; P
 0.02), TVP-986
(EC50 values 15- to 80-fold lower; P 
 0.05), and H-241 (EC50
values 5- to 14-fold lower) compared to experiments at 37°C. This
pattern also was seen for EC90 values after 40°C preincubation
with fusion loop MAbs and TVP-376 (EC90 of 112 to 640 ng/ml)
and TVP-986 (EC90 of 281 to 644 ng/ml). A more modest im-
provement in neutralization by fusion loop-specific MAbs was
observed with P75-514 (EC50 values 2- to 15-fold lower), but the
change did not attain statistical significance, likely secondary to
the better baseline inhibition achieved after incubation at 37°C.
Even under conditions of a higher-temperature incubation,
H-241 remained relatively resistant to neutralization by several of
the fusion loop-specific MAbs.
As our data with DENV-4 1036 suggested that modifying the
incubation conditions had less impact on the inhibitory activity of
the type-specific MAbs DV4-E75 and DV4-E88, we evaluated this
FIG 2 Neutralization of DENV serotypes by cross-reactive MAbs that map to fusion loop epitope in DII. (A) Increasing concentrations of purified fusion
loop-specific MAbs (E60, E86, E106, and E119) were mixed with 102 PFU of DENV-1 (strain 16007), DENV-2 (strain 16681), or DENV-3 (strain 16652) (left,
middle, and right, respectively) for 1 h at 37°C. Virus-MAb complexes were added toVero cells, and neutralizationwas assessed in a FRNT assay after comparison
to virus that was incubated with no antibody. The data are representative of at least three independent experiments performed in duplicate. (B) Flow cytometry
histograms of Vero cells infectedwithDENV-4 (strain 1036) and stainedwithWNVE16 (negative control), DV4-E75,DV4-E88, E60, E86, E106, or E119. Results
are representative of several independent experiments. All histograms show the number of cells on the y axis and staining with individual anti-E MAbs on the x
axis. (C) Increasing concentrations of E60, E86, E106, and E119 were mixed with 102 PFU of the DENV-4 (strain 1036) for 1 h at 37°C (left) or 40°C (right), and
neutralization was assessed in a FRNT assay. The data are representative of at least three independent experiments performed in duplicate.
TABLE 3 Neutralization of DENV-1, DENV-2, and DENV-3 by cross-reactive fusion loop-specific MAbsa
MAb Isotype
DENV-1 DENV-2 DENV-3
EC50 (ng/ml) EC90 (ng/ml) EC50 (ng/ml) EC90 (ng/ml) EC50 (ng/ml) EC90 (ng/ml)
E60 IgG2a 21 661 119 537 612 	5,000
E86 IgG2a 83 450 34 343 264 2,089
E106 IgG2a 47 309 15 275 84 	5,000
E119 IgG2a 59 406 17 491 130 2,500
a Increasing concentrations (5 to 5,000 ng/ml) of the indicated MAbs were premixed with 102 FFU of DENV-1 (strain 16007), DENV-2 (strain 16681), or DENV-3 (strain 16652)
for 1 h at 37°C. Virus-MAb mixtures were added to Vero cell monolayers for 1 h at 37°C prior to addition of a methylcellulose overlay. DENV-infected foci were stained with a
human-mouse chimeric E18 MAb. EC50 and EC90 values were determined by using nonlinear regression models (GraphPad Prism). The results are the averages of three
independent experiments performed in triplicate.
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with the strains H-241, TVP-376, TVP-986, and P75-514 (Table
6). Under standard 1-h preincubation conditions at 37°C, DV4-
E75 neutralized the homologous genotype II strains TVP-376 and
TVP-986 efficiently, with EC50 and EC90 values of 91 to 140 ng/ml
and 769 to 1,127 ng/ml, respectively. However, DV4-E75 had little
or no inhibitory activity against the heterologous sylvatic and ge-
notype I strains P75-514 and H-241 (EC50,	5,000 ng/ml), which
is consistent with the genotype-dependent effects on neutraliza-
tion that have been observed with MAbs against DENV-2 and
DENV-3 (36, 37, 61). Under similar conditions, DV4-E88 effi-
ciently neutralized TVP-376 andTVP-986 (EC50 and EC90 of 60 to
80 ng/ml and 317 to 407 ng/ml, respectively), showed an10-fold
decrease in activity against P75-514 (EC50 of 530 ng/ml and EC90
of 3,420 ng/ml), and poorly inhibited infection by H-241 (EC50 of
5,000 ng/ml and EC90 of	5,000 ng/ml).
Increasing the duration of incubation at 37°C or raising the
temperature to 40°C had a smaller impact on neutralization of the
other DENV-4 strains by the DV4-E75 and DV4-E88 MAbs (Ta-
ble 6). For example, against TVP-376 and TVP-986, the EC50 and
EC90 values improved marginally from 1.5- to 3-fold after a 3-h
incubation at 37°C or 1-h incubation at 40°C. We also observed
only slightly improved inhibition of P75-514 by DV4-E75 under
analogous conditions, with EC50 values of 2,522 and 2,873 ng/ml.
For DV4-E88, less-than-2-fold changes in neutralization of P75-
514 were observed under conditions of a longer incubation or
higher temperature. Moreover, little improvement in neutraliza-
tion ofH-241was observed under these conditions. As neutraliza-
tion activities of several genetically diverse DENV-4 strains by
DV4-E75 and DV4-E88 were not altered by preincubation condi-
tions, their epitopes likely are exposed similarly or not at all on the
different temperature-dependent conformational ensembles of
the virus.
Effect of time and temperature on other DENV-4 MAbs. As
the neutralizing activities of the fusion loop MAbs against
DENV-4 were considerably stronger after incubation at 40°C, we
speculated that some of our other newly generatedDENV-4MAbs
with modest neutralizing activities against DENV-4 1036 (Table
2) might show greater inhibitory activity under similar condi-
tions, or against the relatively divergent DENV-4 P75-514 strain.
To test this, we compared the inhibitory activities of neat and
diluted (1/5 and 1/25) hybridoma supernatants after preincuba-
tion of DENV-4 for 1 h at 37°C or 40°C (Table 7). Many of the
MAbs tested (DV4-E3, DV4-E4, DV4-E27, DV4-E29, DV4-E33,
DV4-E40, DV4-E68, DV4-E72, DV4-E76, DV4-E78, and DV4-
E87) showed improved inhibitory activity against one or both of
the DENV-4 1036 or P75-514 strains, and this was most apparent
at higher dilutions of supernatant. In comparison, some MAbs
(DV4-E121 and DV4-E138) showed marginal improvement
when higher temperatures of incubation were used.
Epitope mapping of neutralizing DENV-4 MAbs. To under-
stand in greater detail the underlying basis of variation in inhibi-
tory potential of the neutralizing MAbs, we mapped the domains
and amino acid residues required for MAb binding by using mul-
tiple approaches.
(i) Domain recognition. MAbs were screened initially for E
protein domain recognition by using yeast that expressed
DENV-4 DI-II, DIII, or the E ectodomain (DI-DII-DIII) (Table 2
and data not shown; see also Table S1 in the supplemental mate-
rial). Seventeen MAbs in the panel bound to yeast expressing DI-
II, 20 MAbs recognized DIII on yeast, and 10 MAbs failed to bind
to either DI-DII or DIII yet still bound to the E ectodomain on
yeast, suggesting a recognition site that possibly spans multiple
domains. Thirty-one MAbs failed to bind any of the three yeast
constructs, and three (nonneutralizing)MAbs were not tested. Of
the 13 MAbs in our panel with relatively moderate to strong neu-
tralizing activity against DENV-4 strains (including under higher-
temperature or longer-incubation conditions), 3 bound epitopes
in DI-II and 10 recognized sites in DIII.
(ii) Neutralization escape. As two of our strongly inhibitory
MAbs (DV4-E75 and DV4-E88) recognized a determinant on
DENV-4 that was not present on yeast-displayed DI-DII or DIII,
we selected neutralization escape mutants against strain DENV-4
1036 and DENV-4 TVP-376 to begin to define their epitopes.
After sequential passage of DENV-4 1036 on Vero cells under
DV4-E75 selection, we identified an escape variant (Fig. 3A) that
was no longer neutralized efficiently. Viral sequence from plaque-
purified escape variantswas compared to virus passaged in parallel
in the absence of MAb selection. All (6 of 6) escape variants
uniquely had a G330E mutation, which corresponds to a site
within the BC loop ofDIII.WhenDENV-4TVP-376was passaged
under DV4-E75 selection, we identified a different escape variant
(Fig. 3B). Sequencing (6 of 6) purified plaques revealed two mu-
tations, at T361A and V364I, which correspond to residues in the
CC= loop of DIII. For DV4-E88, we were unable to select a neu-
tralization escape variant against either DENV-4 1036 or TVP-
376.
(iii) Binding to mutant prM-E proteins in mammalian cells.
To gain additional insight as to where our strongly neutralizing
anti-DENV-4 MAbs bound, we screened DV4-E4, DV4-E29,
DV4-E33, DV4-E40, DV4-E75, DV4-E76, DV4-E78, DV4-E87,
DV4-E88, and DV4-E121 against a comprehensive DENV-4 mu-
tation library in which nearly every residue within prM and E (see
TABLE 4 Neutralization of DENV-4 strain 1036 by cross-reactive fusion
loop- and type-specific MAbsa
MAb Temp (°C) Time (h) EC50 (ng/ml) EC90 (ng/ml)
E60 37 1 2,786 	5,000
E60 37 3 833 	5,000
E60 40 1 34 195
E86 37 1 822 	5,000
E86 37 3 232 	5,000
E86 40 1 23 125
E106 37 1 1,141 	5,000
E106 37 3 271 	5,000
E106 40 1 35 178
E119 37 1 1,730 	5,000
E119 37 3 598 	5,000
E119 40 1 73 442
DV4-E75 37 1 63 258
DV4-E75 37 3 36 181
DV4-E75 40 1 36 103
DV4-E88 37 1 18 49
DV4-E88 37 3 9 34
DV4-E88 40 1 17 51
a Increasing concentrations (5 to 5,000 ng/ml) of the indicated MAbs were premixed
with 102 FFU of DENV-4 (strain 1036) for 1 h at 37°C, 3 h at 37°C, or 1 h at 40°C.
Virus-MAb mixtures were added to Vero cell monolayers for 1 h at 37°C prior to
addition of a methylcellulose overlay. DENV-infected foci were stained with a human-
mouse chimeric E18 MAb. EC50 and EC90 values were determined by using nonlinear
regression models (GraphPad Prism). The results are the averages of three independent
experiments performed in triplicate.
Sukupolvi-Petty et al.
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Materials and Methods) was mutated individually to an alanine
(alanine residues were mutated to serine). Each mutant protein
clone was expressed in HEK-293T cells and assessed for intracel-
lular MAb antibody binding by using high-throughput flow cy-
tometry on permeabilized cells. Themean fluorescence was deter-
mined, andMAb reactivity to each mutant was calculated relative
to reactivity to theWTDENV-4 prM-E protein (Fig. 4 and Table 8).
Clones were identified as crucial for binding if they had low reac-
tivity to individual MAbs but high reactivity to other DENV-4-
specific control MAbs. This counterscreen strategy facilitated the
exclusion of prM-E mutants that are globally or locally misfolded
or that have an expression defect (53).
For MAb DV4-E4, four amino acids within the fusion loop of
DII were identified as critical for recognition (Fig. 4A). When
TABLE 5 Neutralization of other DENV-4 strains by cross-reactive fusion loop MAbs
Virusa Genotypeb MAb Temp (°C) Time (h) EC50 (ng/ml) EC90 (ng/ml)
H241 I E60 37 1 	5,000 	5,000
H241 I E60 37 3 1,171 	5,000
H241 I E60 40 1 65 711
H241 I E86 37 1 	5,000 	5,000
H241 I E86 37 3 2,534 	5,000
H241 I E86 40 1 95 700
H241 I E106 37 1 4,500 	5,000
H241 I E106 37 3 1,472 	5,000
H241 I E106 40 1 183 1,750
H241 I E119 37 1 	5,000 	5,000
H241 I E119 37 3 	5,000 	5,000
H241 I E119 40 1 267 	5,000
TVP-376 II E60 37 1 1,054 	5,000
TVP-376 II E60 37 3 153 3,524
TVP-376 II E60 40 1 10 113
TVP-376 II E86 37 1 594 	5,000
TVP-376 II E86 37 3 95 2,104
TVP-376 II E86 40 1 9 285
TVP-376 II E106 37 1 510 	5,000
TVP-376 II E106 37 3 121 2,864
TVP-376 II E106 40 1 9 166
TVP-376 II E119 37 1 1,165 	5,000
TVP-376 II E119 37 3 213 	5,000
TVP-376 II E119 40 1 105 640
TVP-986 II E60 37 1 900 	5,000
TVP-986 II E60 37 3 56 548
TVP-986 II E60 40 1 11 282
TVP-986 II E86 37 1 756 	5,000
TVP-986 II E86 37 3 22 832
TVP-986 II E86 40 1 31 644
TVP-986 II E106 37 1 458 	5,000
TVP-986 II E106 37 3 51 809
TVP-986 II E106 40 1 22 411
TVP-986 II E119 37 1 546 	5,000
TVP-986 II E119 37 3 60 2,259
TVP-986 II E119 40 1 37 621
P75-514 S E60 37 1 268 2,317
P75-514 S E60 37 3 45 313
P75-514 S E60 40 1 38 454
P75-514 S E86 37 1 98 1,758
P75-514 S E86 37 3 25 214
P75-514 S E86 40 1 58 306
P75-514 S E106 37 1 136 1,312
P75-514 S E106 37 3 30 285
P75-514 S E106 40 1 33 210
P75-514 S E119 37 1 99 1,507
P75-514 S E119 37 3 23 380
P75-514 S E119 40 1 7 115
a Increasing concentrations (5 to 5,000 ng/ml) of the indicated MAbs were premixed with 102 FFU of DENV-4 (strain H241, TVP-376, TVP-986, or P75-514) for 1 h at 37°C, 3 h at
37°C, or 1 h at 40°C. Virus-MAb mixtures were added to Vero cell monolayers for 1 h at 37°C prior to addition of a methylcellulose overlay. DENV-4-infected foci were stained
with a human-mouse chimeric E18 MAb. EC50 and EC90 values were determined by using nonlinear regression models (GraphPad Prism). The results are the averages of three
independent experiments performed in triplicate.
b Summary of genotypes: H-241 is genotype I; 1036, TVP-376, and TVP-986 are genotype II; P75-514 is the sylvatic genotype (S).
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residue R99, G102G106, or L107wasmutated to alanine, DV4-E4
binding activity was significantly lower than binding to the WT
protein, whereas other MAbs showed strong reactivities against
these fusion loop mutants. The remaining neutralizing MAbs in
our panel that were subjected to mapping by this method showed
loss of binding when residues in DIII were mutated that corre-
sponded to previously described epitopes for mouse and human
MAbs against other DENV serotypes (35–38, 44). These included
residues in the N-terminal linker region (M301; DV4-E75 and
DV4-E87), A-strand (K310;DV4-E40), B-strand (K325;DV4-E76
and DV4-E121), BC loop (A331; DV4-E88 and DV4-E121), CC=
loop (E338 [DV4-E76, DV4-E78, andDV4-E87]; V347DV4-[E76
andDV4-E87]; V348 [DV4-E76]), D-strand (P356; DV4-E76 and
DV4-E87), DE loop (T361; DV4-E75, DV4-E88, and DV4-E121),
F-strand (D375 [DV4-E33 andDV4-E40]; Y377 [DV4-E29, DV4-
E33, and DV4-E40]), and G-strand (L387 [DV4-E88]; H390
[DV4-E29, DV4-E33, and DV4-E40]; F392 [DV4-E33 and DV4-
E40]) (Fig. 4B to J and L to N).
Three of the type-specific neutralizingMAbs (DV4-E75, DV4-
E88, andDV4-E121) that mapped to epitopes within DIII showed
variable inhibitory activities against strains corresponding to het-
erologous genotypes. Given this, we sequenced the prM and E
genes from all five viral strains (H-241 [genotype I], 1036 [geno-
type II], TVP-376 [genotype II], TVP-986 [genotype II], and P75-
514 ([sylvatic genotype]) and performed an alignment to assess
strain variation in amino acid residues that were identified as im-
portant for MAb binding. Notably, we observed variation in the
D-strand and the DE loop among the different strains (Fig. 4K).
H-241 uniquely had a bulky tyrosine at position 360 instead of an
asparagine, whereas H-241 and P75-514 both had a large phenyl-
alanine at residue 357 compared to the genotype II strains which
encoded a leucine. These sequence changes in combination with
themapping data likely explain the loss of neutralizing activities of
DV4-E75, DV4-E88, and DV4-E121 against the genotype II
and/or the sylvatic strain.
Protective activities in mice of type-specific and cross-reac-
tive anti-DENV-4MAbs.Todefine the relationship between neu-
tralization in cell culture and protection in vivo, we developed two
newmouse models of DENV-4 infection, corresponding to infec-
tion with strains of two different genotypes. While prior studies
have published mouse models of DENV-1, DENV-2, and
DENV-3 infection, no lethal peripheral inoculation model of
adult mice with DENV-4 has been published. Based on experi-
ments with other DENV serotypes (54, 62), we infected IFN-
R/ IFN-R/ immunodeficient AG129 mice with 104 to
106 PFU of different DENV-4 strains (1036, H-241, TVP-986, and
TVP-376). Although mice were followed for 40 days, no morbid-
ity or mortality was observed after infection with 1036, H-241 or
TVP-986, and only some mice became ill after infection with
TVP-376 infection, with this occurring late in the time course.We
passaged the H-241 genotype I strain between mice and C6/36
insect cells, as was done previously to generate a mouse-adapted
DENV-2 strain (62). After several passages, we identified an iso-
late that exhibited virulence in AG129 mice, resulting in 100%
lethality at day 8 after infection with 5 104 PFU of virus (Fig. 5A
and B). We used this model to test the efficacy of several of our
MAbs in vivo, even though in general, H-241 was relatively resis-
tant to neutralization in vitro compared to the other DENV-4
TABLE 6 Neutralization of other DENV-4 strains by type-specific MAbsa
Virus Genotype MAb Temp (°C) Time (h) EC50 (ng/ml) EC90 (ng/ml)
H241 I DV4-E75 37 1 	5,000 	5,000
H241 I DV4-E75 37 3 	5,000 	5,000
H241 I DV4-E75 40 1 	5,000 	5,000
H241 I DV4-E88 37 1 	5,000 	5,000
H241 I DV4-E88 37 3 4,593 	5,000
H241 I DV4-E88 40 1 	5,000 	5,000
TVP-376 II DV4-E75 37 1 140 1,127
TVP-376 II DV4-E75 37 3 73 656
TVP-376 II DV4-E75 40 1 57 471
TVP-376 II DV4-E88 37 1 80 407
TVP-376 II DV4-E88 37 3 58 337
TVP-376 II DV4-E88 40 1 47 331
TVP-986 II DV4-E75 37 1 91 769
TVP-986 II DV4-E75 37 3 29 311
TVP-986 II DV4-E75 40 1 47 417
TVP-986 II DV4-E88 37 1 60 317
TVP-986 II DV4-E88 37 3 25 171
TVP-986 II DV4-E88 40 1 46 294
P75-514 S DV4-E75 37 1 	5,000 	5,000
P75-514 S DV4-E75 37 3 2,522 	5,000
P75-514 S DV4-E75 40 1 2,873 	5,000
P75-514 S DV4-E88 37 1 531 3,420
P75-514 S DV4-E88 37 3 248 2,535
P75-514 S DV4-E88 40 1 352 2,133
a Increasing concentrations (5 to 5,000 mg/ml) of the indicated DV4 type-specific MAbs were premixed with 102 FFU of DENV-4 (strain H241, TVP-376, TVP-986, or P75-514) for
1 h at 37°C, 3 h at 37°C, or 1 h at 40°C. Virus-MAb mixtures were added to Vero cell monolayers for 1 h at 37°C prior to addition of a methylcellulose overlay. DENV-4-infected
foci were stained with a human-mouse chimeric E18 MAb. EC50 and EC90 values were determined by using nonlinear regression models (GraphPad Prism). The results are the
averages of three independent experiments performed in triplicate. Summary of genotypes: H-241 is genotype I; 1036, TVP-376, and TVP-986 are genotype II; P75-514 is the
sylvatic genotype (S).
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strains (Tables 5 and 6). A single dose (100 g) of DV4-E88 or
three different cross-reactive fusion loop MAbs (E60, E86, and
E119) prior to infection provided only modest protection, as the
mean survival time was extended by 2 to 3 days (P
 0.004) com-
pared to animals who received PBS or the isotype control (CHK-
112) MAb (Fig. 5C). However, these MAbs failed to decrease the
mortality rate after infection with DENV-4 H-241, even when
higher doses (500 g) were used (data not shown).
Because theDENV-4H-241was resistant to neutralization and
protection by several MAbs, we passaged the TVP-376 (genotype
I) strain for further analysis. After one passage in mice, an isolate
was obtained that caused 100% lethality in AG129mice (Fig. 5D).
After two successive passages, inoculation with a higher dose (p2;
105 PFU) resulted inmore rapid death (Fig. 5E). A single dose (250
g) of DV4-E88 or of the cross-reactive fusion loop MAb E119
prior to infection provided significant protection (50 to 63%; P

0.001) against DENV-4 TVP-376 compared to PBS or the isotype
control (CHK-267) MAb (Fig. 5F). Thus, for DENV-4 strains
H-241 and TVP-376, the in vivo protection results correlated with
focus reduction neutralization titers of type-specific or cross-re-
active MAbs after preincubation at 37°C.
DISCUSSION
Despite the induction of neutralizing antibodies against all four
DENV serotypes, the most advanced tetravalent live-attenuated
DENV vaccine candidate for humans showed a poor 30% overall
efficacy rate in a recently published phase 2b clinical trial (5).
Thus, there is a pressing need for an improved understanding of
the correlates of protection, especially those of neutralizing anti-
bodies. To define in greater detail the structural and molecular
correlates of antibody protection against DENV, we and others
have generated and evaluated panels of mouse and human MAbs
for their neutralizing activities, epitope binding patterns, and in
vivo protective capacities (35–38, 44, 49, 63–69). In this study, we
developed a new panel of anti-DENV-4MAbs by using an immu-
nization strategy with infectious DENV-4 that had successfully
generated neutralizing antibodies against DENV-1 (35), DENV-2
(38), DENV-3 (37), and WNV (52). Despite screening 6,000 hy-
bridomas as part of 10 independent fusions, unexpectedly, we
identified a relatively small number of MAbs that inhibited
DENV-4, and none that reached the potency that was observed
with MAbs against other flaviviruses. Remarkably, we observed
strain- and temperature-dependent neutralization by MAbs that
mapped to distinct epitopes onDII andDIII of the E protein. This
TABLE 7 Neutralization of DENV-4 strains 1036 (genotype I) and P75-
514 (sylvatic genotype) based on a panel of DENV-4 MAbsa
Virus MAb Temp (°C)
% neutralization of
supernatant at dilution of:
Neat 1:5 1:25
1036 DV4-E3 37 94 58 29
1036 DV4-E3 40 100 98 72
P75-514 DV4-E3 37 99 91 63
P75-514 DV4-E3 40 99 99 86
1036 DV4-E4 37 84 23 1
1036 DV4-E4 40 99 83 33
P75-514 DV4-E4 37 94 69 35
P75-514 DV4-E4 40 97 92 78
1036 DV4-E27 37 68 24 6
1036 DV4-E27 40 82 38 12
P75-514 DV4-E27 37 89 53 29
P75-514 DV4-E27 40 98 92 70
1036 DV4-E29 37 69 36 15
1036 DV4-E29 40 95 78 50
P75-514 DV4-E29 37 60 31 20
P75-514 DV4-E29 40 78 59 51
1036 DV4-E33 37 90 70 32
1036 DV4-E33 40 99 92 65
P75-514 DV4-E33 37 99 90 80
P75-514 DV4-E33 40 100 100 97
1036 DV4-E40 37 79 40 23
1036 DV4-E40 40 98 78 50
P75-514 DV4-E40 37 95 79 58
P75-514 DV4-E40 40 99 98 89
1036 DV4-E68 37 63 32 16
1036 DV4-E68 40 88 70 29
P75-514 DV4-E68 37 79 39 11
P75-514 DV4-E68 40 95 82 47
1036 DV4-E72 37 16 0 0
1036 DV4-E72 40 21 4 0
P75-514 DV4-E72 37 43 7 11
P75-514 DV4-E72 40 84 74 70
1036 DV4-E76 37 91 49 23
1036 DV4-E76 40 100 96 61
P75-514 DV4-E76 37 95 64 30
P75-514 DV4-E76 40 97 84 68
1036 DV4-E78 37 79 32 6
1036 DV4-E78 40 97 76 34
P75-514 DV4-E78 37 85 33 5
P75-514 DV4-E78 40 91 60 6
1036 DV4-E87 37 68 27 9
1036 DV4-E87 40 90 56 24
P75-514 DV4-E87 37 87 50 17
P75-514 DV4-E87 40 90 73 32
1036 DV4-E121 37 100 93 57
1036 DV4-E121 40 100 96 64
P75-514 DV4-E121 37 45 4 16
P75-514 DV4-E121 40 24 14 31
TABLE 7 (Continued)
Virus MAb Temp (°C)
% neutralization of
supernatant at dilution of:
Neat 1:5 1:25
1036 DV4-E138 37 28 7 3
1036 DV4-E138 40 31 8 9
P75-514 DV4-E138 37 52 18 5
P75-514 DV4-E138 40 53 28 25
a Hybridoma supernatant (neat or diluted) was incubated with 102 FFU of DENV-4
(strain 1036 or P75-514) for 1 h at 37°C or 40°C. Virus-MAb mixtures were added to
Vero cell monolayers for 1 h at 37°C prior to addition of a methylcellulose overlay.
DENV-infected foci were stained with a human-mouse chimeric E18 MAb. The percent
neutralization was determined compared to medium alone. Results are representative
of three independent experiments.
MAb Neutralization of DENV-4





ber 1, 2014 by W






was most apparent with DII fusion loop MAbs, which strongly
neutralizedDENV-1,DENV-2, andDENV-3 yet onlyweakly neu-
tralized five different DENV-4 strains despite complete epitope
sequence conservation. Thus, DENV-4 may have a unique virion
conformation relative to other DENV serotypes that results in
poor fusion loop accessibility.
Neutralization of DENV-4 by MAbs. While many neutraliz-
ing MAbs against DENV-1, DENV-2, and DENV-3 have been
reported, curiously, fewer inhibitory MAbs against DENV-4 have
been described.Of the few type-specific strongly neutralizing anti-
DENV-4 MAbs that have been characterized, fewer data exist re-
garding strain dependence, epitope specificity, or functional ac-
tivity in vivo. A study by Morens et al. (40) produced 19 mouse
MAbs against DENV-4 (strain 4328-S): only one (UH-6C3) was
serotype specific and strongly neutralizing (PRNT50 of 50 ng/
ml), and no additional functional testing was performed with dif-
ferentDENV-4 strains. Forty-threeMAbs against DENV-4 (strain
H-241) were generated by Yamanaka et al. (41): only two were
serotype specific (D4-II-12B2 and D4-I-11D11) and neutralizing,
and no strain dependence or mapping was performed. Two type-
specific anti-DENV-4 chimpanzee MAbs (5D9 and 5H2) were
generated after immunization with DENV-4 (strain 814669; Ca-
ribbean); these MAbs inhibited infection of the homologous
strain (PRNT50 of 580 and 240 ng/ml, respectively) (42). The 5H2
MAb, which localized to an epitope in domain I (amino acid res-
idues K174 and P176) of the E protein (43), neutralized two other
DENV-4 isolates (H-241 [Philippines] and 341750 [Caribbean])
from similar and distinct geographic regions (42) and also pro-
tected suckling mice from lethal DENV-4 H-241 infection when
administered as prophylaxis. A recombinant variant of 5H2 lack-
ing the ability to bind Fc receptors protected monkeys from
viremia after challenge with DENV-4 814669. Only two human
type-specific neutralizing MAbs (DV16.8 and DV22.3) against
DENV-4 have been reported (44). These MAbs were generated
from a subject 200 days after primary DENV-4 infection, recog-
nized an epitope in DI-DII, and neutralized efficiently (EC50 of 6
to 39 ng/ml by flow cytometric assay) infection by a DENV-4
vaccine strain. Why have so relatively few type-specific DENV-4-
neutralizing MAbs been described? The answer remains uncer-
tain, although it could reflect a bias of study in the DENV field
toward detailed investigation with other serotypes, or a difficulty
in identifying strongly inhibitory anti-DENV-4MAbs when using
conventional neutralization assays.
An intriguing finding of our study was that cross-reactive DII-
specific fusion loopMAbs, which efficiently inhibited infection of
other DENV serotypes, poorly neutralized all five DENV-4 strains
after a standard 37°C 1-h preincubation. Thus, under these exper-
imental conditions, fusion loop MAbs neutralized DENV-4 inef-
ficiently, in amanner analogous to that seen withmature forms of
WNV (45, 70, 71). However, lengthening the time or increasing
the temperature of incubation resulted in improved neutraliza-
tion of DENV-4 strains by all fusion loopMAbs tested. This result
suggests that under standard 37°C preincubation conditions, the
fusion-loop epitope on DENV-4, in contrast to other DENV se-
rotypes, is not sufficiently accessible to reach a stoichiometry of
binding required for neutralization (72). However, increasing the
time and/or temperature of preincubation enhances exposure of
the fusion loop epitope, which allows MAb binding and DENV-4
neutralization. What is unique about DENV-4 compared to the
other DENV serotypes? We hypothesize that two interrelated
physical processes govern this: (i) DENV-4 “breathing” creates
unique structural ensembles (57, 58, 60) compared to other
DENV serotypes under standard incubation conditions, such that
the fusion loop epitope remains inaccessible; (ii) DENV-4 is more
mature than other DENV serotypes. The maturation state of the
virion, which is modified by cleavage of prM by furin-like pro-
teases in the trans-Golgi network, modulates the sensitivity to
neutralization by many classes of MAbs, including those binding
fusion loop-specific epitopes. Given that the neutralization phe-
notype of fusion loop MAbs of DENV-4 resembles that seen with
WNV (45, 58, 71), we speculate that the structure and/or behavior
of the DENV-4 virion may be more similar to WNV than other
DENV serotypes.
DENV-4 MAb epitope exposure.Many of our anti-DENV-4-
neutralizing MAbs that mapped to DIII also showed time- and
temperature-dependent improvement in neutralization of
FIG 3 Selection of neutralization escape mutants of DV4-E75. The graphs show results of the focus reduction neutralization assays with bulk virus (DENV-4
1036 (A) or DENV-4 TVP-376 (B) obtained after six passages under selection withmedium (WT) or DV4-E75 on Vero cells. Results are representative of at least
three independent experiments performed in triplicate and were normalized to the no-MAb control.
Sukupolvi-Petty et al.
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FIG 4 Structural basis of neutralization of DENV-4 by MAbs. (A to J) Mapping of MAbs based on prM-E protein epitope mutants that were expressed
intracellularly in HEK-293T cells (see Materials and Methods). For each panel, the blue bar reflects binding of the interrogated MAb. Although binding to a
limited set of mutants is shown for eachMAb, no differences were observed with other prM-E protein variants corresponding to changes in virtually any amino
acids of the E protein (data not shown). The results are the averages of at least two independent experiments for eachMAb with each mutant protein. Error bars
indicate ranges, and asterisks denote differences that were statistically significant compared to binding to the WT prM-E protein (P 
 0.05). (K) Sequence
alignment of different DENV-4 genotypes andmapping of neutralizingMAbs. The sequences from five strains of DENV-4 DIII (strain H241, genotype 1; strain
1036, genotype II; strain TVP-376, genotype II; strain TVP-986, genotype II; strain P75-514, sylvatic) were aligned and assigned the secondary structure described
for the DENV-4 DIII structure (PDB ID 3UAJ) for residues 295 to 400. Black blocks highlight the sites of genotypic variation. Results of the epitopemapping are
denoted underneath in red according to the number of neutralizing MAbs in our panel that lost binding when a specific amino acid was mutated. The colored
boxes correspond to specific neutralizing antibody and structural recognition determinates, as follows: lateral ridge, blue; A-strand, cyan;C-strand,CC= loop, and
C=-strand,magenta; F- andG-strands, green. (L toN) Localization of neutralizing epitopes onDENV-4DIII, as determined by neutralization escape and staining
of permeabilized cells expressing mutant prM-E proteins. The ribbon diagram shows the DENV-4 DIII structure (PDB ID 3UAJ) with amino acid residues that
affect binding of neutralizing MAbs colored according to the major epitope. (L) DV4-E33 (F- and G-strand epitopes; green); (M) DV4-E76 (CC= loop epitope;
magenta); (N) DV4-E88 (lateral ridge epitope; blue).
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DENV-4 1036, with the exception of three, DV4-E75, DV4-E88,
and DV4-E121. These three MAbs shared a loss-of-binding phe-
notype at residues T361 in the DE loop in contrast to the others,
which recognized sites in BC loop, CC= loop, FG loop, or
G-strand. These data suggest that for DENV-4 1036, the DE loop
epitope is highly accessible on DIII. Of note, several of the DIII-
specific anti-DENV-4 MAbs showed less temperature-dependent
neutralization with the sylvatic strain P75-514, which suggests
there may be strain- or genotype-dependent differences in virion
structure, maturation, or ensembles of conformations.
Variation in neutralization of different genotypes within a se-
rotype by type-specific antibodies against DENV-1, DENV-2, and
DENV-3 suggests that the limited amino acid dissimilarity that
occurs within a DENV serotype can impact the broad-spectrum
inhibitory activity of some antibodies (35–37, 60). Indeed, this
property may apply to polyclonal responses and has been sug-
gested as an explanation for the poor protective efficacy of a live
tetravalent DENV vaccine against a circulating DENV-2 strain (5,
73). Our results confirmed this observation for DENV-4. DV4-
E75 and DV4-E88 strongly neutralized genotype II strains (1036,
TVP-376, and TVP-986) but either failed to or only weakly inhib-
ited infection with genotype I or sylvatic strains. Analogously,
DV4-E121 showed a markedly reduced capacity to neutralize in-
fection of the sylvatic strain. Sequence alignment of all five strains
revealed genotypic variation in amino acids of the D-strand and
DE loop,which corresponds to residues that contribute to binding
of theseMAbs. The DE loop is a solvent-accessible region onDIII,
which has been implicated in the binding of strongly neutralizing
antibodies against other flaviviruses, including WNV (74, 75).
Based on these data and published results with other MAbs, we
suggest that it may be important to assess whether polyclonal an-
tibody responses in the context of a vaccine generated against an
individual strain will neutralize infection of heterologous geno-
types effectively. This may be especially true for DENV-4, given
the variation of both type-specific and cross-reactive MAbs in
neutralizing infections with strains corresponding to different ge-
notypes. Indeed, sera from humans immunized with a DENV-4
live-attenuated vaccine candidate (DENV430) showed weak to
modest neutralization (PRNT60 of 20 to 40 at 180 days) of heter-
ologous DENV-4 strains, with some individuals failing to neutral-
ize infection at all of the strains corresponding to heterologous
DENV-4 genotypes (32).
Some of our DENV-4 DIII-specific MAbs (e.g., DV4-E75 and
DV4-E88) mapped to DIII by neutralization escape or shotgun
mutagenesis yet failed to bind DIII when displayed on the surface
of yeast. Although structural studies are warranted to definitively
resolve this apparent paradox, we suggest three possible explana-
tions. (i) DIII displayed on yeast fails to adopt a native structure
and, thus, does not present all MAb epitopes. While possible, this
seems less likely, given that the vast majority of our DIII-specific
MAbs against DENV-1, DENV-2, DENV-3, and WNV have rec-
ognized a similarly designed yeast-displayed DIII (35, 37, 38, 49,
52). Moreover, even in our current study, most of the DENV-4
DIII-specific neutralizing and nonneutralizing MAbs recognized
DIII when displayed on yeast. (ii) DV4-E75 and DV4-E88 MAbs
have recognition sites in DIII (identified by neutralization escape
or shotgun mutagenesis) and other regions of the E protein that
would not be presented on isolated DIII proteins. Indeed, prior
studies with neutralizing anti-WNV or anti-DENV humanMAbs
identified composite structural epitopes comprised of sites in
multiple domains on adjacent E protein dimers (69, 76, 77). (iii)
These MAbs require bivalent interactions to bind DIII, such that
monovalent binding on the surfaces of yeast cells is too weak in
nature to detect. Indeed, we recently identified bivalent neutraliz-
ing MAbs against DENV-1 that map to adjacent epitopes on DIII
(M. Barrow, M. Diamond, and D. Fremont, unpublished obser-
vations).
Mouse models of DENV-4 infection. In this study, we devel-
oped two newmodels of lethal DENV-4 infection via a peripheral
route in AG129 mice with virus strains corresponding to geno-
types I (H-241) and II (TVP-376) and used these to assess the
protective efficacy of selected cross-reactive and type-specific an-
ti-DENV-4MAbs. Prior to this, only one strain of DENV-1 (West
Pac-74) (35) and two strains of DENV-2 (D2S10 and D2Y98P)
(62, 78, 79) had been reported to cause lethal infection in AG129
mice after peripheral inoculation, with the DENV-2 strains pro-
moting a vascular leakage phenotype that to some extent resem-
bled the DSS seen in humans. In preliminary studies using high
infectious doses of the twoDENV-4 strains, we saw a similar rapid
death phenotype consistent with the shock syndrome that is ob-
served with mouse-adapted DENV-2 strains (46, 62, 80). In com-
parison, at lower DENV-4 doses, the mice survived longer and
developed signs of central nervous system disease, which rarely
occurs in human disease (81). Two mouse-adapted strains
(DENV-2 and DENV-3) have been reported to cause lethal infec-
tion in wild-typemice (82–84), althoughmechanistically how this
occurs remains unknown, as DENV isolates uniformly fail to an-
TABLE 8 Loss-of-binding residues identified by prM-E protein display
on HEK 293T cells
MAb Domain Amino acid residue(s)a Epitopeb
DV4-E4 DII R99, G102, G106, L107 Fusion loop
DV4-E29 DIII Y377 F-strand
H390 G-strand
DV4-E33 DIII D375, Y377 F-strand
H390, F392 G-strand
DV4-E40 DIII K310 A-strand
D375, Y377 F-strand
H390, F392 G-strand
DV4-E75 DIII K325 B-strand
N360, T361 DE loop
DV4-E76 DIII M301 N-terminal linker




DV4-E78 DIII E338, V347, R350 CC= loop
DV4-E87 DIII M301 N-terminal linker
E338, V347 CC= loop
P356 D-strand
DV4-E88 DIII A331 BC loop
T361 DE loop
DV4-E121 DIII K325 B-strand
A331 BC loop
T361 DE loop
a Amino acids were determined based on loss of binding to the indicated MAb by using
prM-E display of a shotgun alanine-scanning mutagenesis library (see Materials and
Methods for details).
b Loops and strands that comprised specific epitopes were assigned based on existing
crystal structures of DIII from DENV-1, DENV-2, and DENV-3 E proteins (17, 19, 20,
89).
Sukupolvi-Petty et al.
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tagonize key innate immune restriction signaling molecules in
mouse cells and in mice, including MITA (also known as STING)
(85, 86) and STAT2 (87, 88). Passive transfer studies in ourmouse
models of DENV-4 infection correlated with in vitro neutraliza-
tion data: poor inhibitory activity in vitro against DENV-4 H-241
was associated with only modest protection in vivo, whereas
greater neutralizing activity against TVP-376 corresponded to
more complete protection against lethal infection. Remarkably,
even the highly cross-reactive fusion loop-specificMAbs that neu-
tralized all other DENV serotypes and had postexposure thera-
FIG 5 Prophylactic efficacies of neutralizing antibodies in mice after DENV-4 infection. (A) Development of the AG129 mouse model with DENV-4 H-241.
Alternating passage of DENV-4 H-241 between mice and C6/36 cells was performed (see Materials and Methods). Virus (1  105 PFU) generated from the
indicated passage (p) cycle was used for intravenous injection of AG129 mice. Animals were monitored for survival over 40 days. Data were generated from two
independent experiments, with 5 to 6mice per experimental group. (B) Dose response of H-241 p7 virus in AG129mice. Virus was administered by intravenous
injection, and survival was followed for 30 days. Data were generated from two independent experiments with 6 mice per experimental group. (C) AG129 mice
were passively transferred via the intraperitoneal route either PBS or 100 g of CHK-112 (isotype control MAb), E60, E86, E119, or DV4-E88 1 day before
infection with 5 104 PFU ofH-241 (genotype I) by an intravenous route.Mice weremonitored for survival for 17 days after infection. The survival curves were
constructed fromdata from three independent experiments. The number of animals ranged from6 to 14 per group. (D)Development of theAG129mousemodel
withDENV-4TVP-376. Successive passage ofDENV-4TVP-376 betweenmicewas performed (seeMaterials andMethods). Virus (5 104 PFU) generated from
the indicated passage (p) cycle was used for intravenous injection of AG129 mice. Animals were monitored for survival over 40 days. Data were generated from
two independent experiments with 8 to 10 mice per experimental group. (E) Dose response of TVP-376 p2 virus in AG129 mice. Virus was administered by
intravenous injection, and survival was followed for 30 days. Data were generated from two independent experiments with 6 to 10mice per experimental group.
(F) AG129 mice were passively transferred via the intraperitoneal route either no MAb or 250 g of CHK-267 (isotype control MAb), E119, or DV4-E88 1 day
before infection with 1 105 PFU of TVP-376 (genotype II) by the intravenous route. Mice were monitored for survival for 30 days after infection. The survival
curves were constructed from data from three independent experiments. The number of animals ranged from 6 to 9 per group.
MAb Neutralization of DENV-4
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peutic activity against DENV-2 infection in vivo (46, 56) showed a
differential ability to protect against the two DENV-4 strains in
mice. Thus, the two DENV-4 models in AG129 mice likely will be
useful for future therapeutic testing, as currently most preclinical
studies rely exclusively on protection data from the DENV-2
D2S10 strain. Future studies will be directed at defining the ge-
netic determinants that enabled these DENV-4 strains to cause
more severe disease in mice.
In summary, we developed a panel of 81 new DENV-4 MAbs
and examined their cross-reactivities, epitope specificities, neu-
tralization potential levels in cell culture, and the protective capac-
ities of a subset of these MAbs in vivo. Our studies established the
complexity of MAb recognition against the genetically divergent
DENV-4 and suggest that differences in epitope exposure and
possibly virion structure relative to other DENV serotypes impact
antibody neutralization. These results may be directly relevant for
understanding serotype-specific protective efficacy in ongoing
human clinical trials with several live-attenuated tetravalent
DENV vaccine candidates.
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